Homocysteine is a bystander for ST-segment elevation myocardial infarction: a case-control study
Abstract Background Homocysteine has been long considered a risk factor for atherosclerosis. However, cardiovascular events cannot be reduced through homocysteine lowering by B vitamin supplements. Although several association studies have reported an elevation of serum homocysteine levels in cardio...
Main Authors: | Ching-Yu Julius Chen, Tzu-Ching Yang, Christopher Chang, Shao-Chun Lu, Po-Yuan Chang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-02-01
|
Series: | BMC Cardiovascular Disorders |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12872-018-0774-8 |
Similar Items
-
Trends in Short‐ and Long‐Term ST‐Segment–Elevation Myocardial Infarction Prognosis Over 3 Decades: A Mediterranean Population‐Based ST‐Segment–Elevation Myocardial Infarction Registry
by: Cosme García‐García, et al.
Published: (2020-10-01) -
Double Culprits in a Patient with ST Elevation Myocardial Infarction: A Challenging But Rewarding Case
by: Eka Ginanjar, et al.
Published: (2018-06-01) -
The Rise and Fall of Routine Manual Thrombectomy for ST-Elevation Myocardial Infarction
by: Vincent Floré, et al.
Published: (2016-04-01) -
Cardiovascular Outcomes of ST-Elevation Myocardial Infarction (STEMI) Patients without Standard Modifiable Risk Factors (SMuRF-Less): The Intermountain Healthcare Experience
by: Jeffrey L. Anderson, et al.
Published: (2022-12-01) -
High time to omit oxygen therapy in ST elevation myocardial infarction
by: Ardavan Khoshnood
Published: (2018-10-01)